Stock comparison
Amicus Therapeutics
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
FOLD
Amicus Therapeutics
Market cap
$4.55B
Sector
Healthcare
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | FOLD | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 42D | 72B | RMD |
| Benjamin Graham | 66D | 75B | RMD |
| Philip Fisher | 52C | 75B | RMD |
| Peter Lynch | 54C | 58C | RMD |
| Joel Greenblatt | 69C | 47D | FOLD |
| Charlie Munger | 41D | 69B | RMD |
| Terry Smith | 37D | 73B | RMD |
Side-by-side metrics
| Metric | FOLD | RMD |
|---|---|---|
| Market cap | $4.55B | $30.18B |
| P/E (TTM) | - | 19.6x |
| EV/EBIT | 139.7x | 17.1x |
| ROIC (TTM) | -6.46% | 19.63% |
| Gross margin | 87.91% | 61.69% |
| Net margin | -4.27% | 27.44% |
| Revenue CAGR 5y | 20.03% | 12.64% |
| EPS CAGR 5y | - | 30.73% |
| Debt / Equity | 1.8x | 0.1x |
| Dividend yield | 0.0% | 1.14% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
FOLD leads on
- P/E (TTM)-vs 19.6x+112%
- Revenue CAGR 5y20.03%vs 12.64%+37%
- Gross margin87.91%vs 61.69%+30%
RMD leads on
- Net margin27.44%vs -4.27%+116%
- ROIC (TTM)19.63%vs -6.46%+103%
- Dividend yield1.14%vs 0.0%+100%
- Debt / Equity0.1xvs 1.8x+93%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.